314 related articles for article (PubMed ID: 17251223)
21. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
22. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment.
Cugno M
Transl Res; 2011 Jan; 157(1):6-9. PubMed ID: 21146145
[No Abstract] [Full Text] [Related]
24. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
25. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
[TBL] [Abstract][Full Text] [Related]
26. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
Van Doornum S; McColl G; Wicks IP
Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
[TBL] [Abstract][Full Text] [Related]
27. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular disease in rheumatoid arthritis.
Kaplan MJ
Curr Opin Rheumatol; 2006 May; 18(3):289-97. PubMed ID: 16582694
[TBL] [Abstract][Full Text] [Related]
29. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study.
Peters MJ; Welsh P; McInnes IB; Wolbink G; Dijkmans BA; Sattar N; Nurmohamed MT
Ann Rheum Dis; 2010 Jul; 69(7):1281-5. PubMed ID: 19934107
[TBL] [Abstract][Full Text] [Related]
30. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
32. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
33. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
34. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
36. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in rheumatoid arthritis.
Suresh E
Postgrad Med J; 2010 Apr; 86(1014):243-50. PubMed ID: 20354048
[TBL] [Abstract][Full Text] [Related]
38. [Accelerated atherosclerosis in rheumatoid arthritis].
Shepshelovich D; Sherer Y; Shoenfeld Y
Harefuah; 2005 Aug; 144(8):561-3, 598. PubMed ID: 16146154
[TBL] [Abstract][Full Text] [Related]
39. [Rheumatoid arthritis--a risk factor of ischemic heart disease].
Hollan I; Mikkelsen K; Førre Ø
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3259-62. PubMed ID: 16327849
[TBL] [Abstract][Full Text] [Related]
40. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.
Radstake TR; Fransen J; Toonen EJ; Coenen MJ; Eijsbouts AE; Donn R; van den Hoogen FH; van Riel PL
Ann Rheum Dis; 2007 Nov; 66(11):1525-30. PubMed ID: 17456524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
